The ability to precisely edit the genomes of bacteria has long been a goal of microbiologists. Such technology would enable ...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), ...
1d
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be ...
A new study finds the proteins responsible for controlling which genes are expressed in a genome do more than simply turn a ...
METRO COMMUNITY COLLEGE CELEBRATES ITS NEW BIOTECHNOLOGY PROGRAM. IT’S. IT’S LAUNCHING AT THE ELKHORN CAMPUS AS KETV NEWSWATCH 7 SCHUYLER REPORTS, THE GOAL IS TO GET STUDENTS READY FOR A RAPIDLY ...
China is pumping money into its biotech industry, helping launch a new wave of labs and incubators in the country. Experts say this could slow down American innovation in the biotech space. China's ...
Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting its extraordinary biodiversity. Food security has become a pressing concern ...
Korean biotechnology company, Nature Cell, is planning to open a stem cell facility in Baltimore, bringing 500 new jobs, the governor announced Tuesday. The 100,000 square foot manufacturing facility ...
Mr. Dreyer is an American editor and writer who lives in Shanghai. See more of our coverage in your search results.Encuentra más de nuestra cobertura en los resultados de búsqueda. Add The New York ...
Sana's allogeneic HIP technology achieved a first in T1D, showing insulin production and immune evasion without immunosuppression, but scalability remains unproven. Despite promising early data, Sana ...
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results